Skip to main content
. 2021 Jul 30;100(30):e26779. doi: 10.1097/MD.0000000000026779

Figure 4.

Figure 4

(A) pMARK immunoreactivity in angiosarcoma of the scalp and face and hemangioma. Angiosarcoma lesions exhibited significantly higher pMAPK immunoreactivity than hemangioma (χ2 = 6.35, P = .012, P < .05). (B) Representative images of immunohistochemical staining of pMAPK in (a) angiosarcoma and (b) hemangioma tissues (SP, ×100). pMAPK = phosphorylated mitogen activated kinase-like protein.